Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Responses to Neo-Antigens in Patients Treated With Raltegravir
NCT00785967Phase 3Withdrawn
- Sponsor
- McGill University Health Centre
- Start
- Jan 2009
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by McGill University Health Centre. Primary endpoint: Percent of patients with phiX174 IgG greater than or equal to 30% of total anti-phiX174 titers. Planned start Jan 2009; status: withdrawn.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00785967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785967.